



Decision Dx·UM

Patient Resource Guide

Understanding
Genomic Testing
in Uveal Melanoma

For more
information visit:
MyUvealMelanoma.com
866-788-9007
option #1

CASTLE
BIOSCIENCES

Getting tested with DecisionDx-UM is simple:



Step 1

Your healthcare provider orders the DecisionDx-UM test



Step 2

Castle Biosciences works with your healthcare provider's team to obtain a tissue sample from your original biopsy



Step 3

Castle Biosciences analyzes your tissue sample with the DecisionDx-UM genomic test



Step 4

Castle Biosciences sends your test results to your healthcare provider, so that they can discuss your individual results with you and determine next steps

CastleTestInfo.com



Uveal (Ocular) Melanoma

After diagnosis of uveal melanoma, also known as ocular melanoma, it is important to gather as much information as possible to help make the best decisions about your treatment. You may be considering the DecisionDx[®]-UM gene expression profile (GEP)

test as part of your clinical care. This guide will help you understand the importance of the test including how the results can be used to personalize your treatment plan.


What is the DecisionDx-UM test?

The DecisionDx-UM test measures the gene expression profile (GEP), or molecular signature of your primary tumor to determine the risk that your tumor will spread (metastasize). The test classifies tumors as Class 1A (low risk), Class 1B (intermediate risk), or Class 2 (high risk) for metastasis within 5 years.

TEST RESULT		RISK OF METASTASIS
Class 1	1A	Low Risk
	1B	Intermediate-Risk
Class 2		High Risk

DecisionDx-UM has been ordered for over 10,300 uveal melanoma patients by more than 350 physicians.

DecisionDx-UM provides risk information that is important in guiding your care following treatment of the original ocular tumor. For instance, if you have a Class 1 (**low risk**) tumor, low-intensity monitoring is likely appropriate. Conversely, if you have a Class 2 (**high risk**) tumor, your healthcare provider may monitor you more intensely, consult additional specialists, and/or discuss clinical trial treatments.



How do I request a test?

If you wish to have the DecisionDx-UM test performed, please discuss it with your healthcare provider before your primary tumor is treated. Only a healthcare provider can order this test.

The DecisionDx-UM test is most commonly run on tumor tissue obtained from a fine needle aspiration biopsy (FNAB) before plaque or proton beam therapy. Your healthcare provider will give you specific information regarding FNAB and any associated risks.

If you are having your eye removed (enucleation), your healthcare provider can

do a FNAB after the eye is removed or the test can be run on preserved sections of your tumor.

Castle Clinical Sample Repository

You can store an additional uveal melanoma tumor sample free of charge for up to 5 years in the Castle Clinical Sample Repository. This sample will be stored for your use only, in case you and your healthcare provider request to take advantage of future developments in uveal melanoma testing. If this program is of interest to you, please visit CastleTestInfo.com/decisiondx-UM/myuvealmelanoma.com.

It is important to note that this program requires an extra sample to be taken and sent to Castle along with the DecisionDx-UM test sample.

How is the test paid for?

Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure payment for your DecisionDx-UM test. Castle will submit your insurance claim and manage the insurance billing process on your behalf. The company also sponsors an industry-leading Patient Assistance Program with the belief that the quality of care should not depend on financial considerations. For more information about insurance coverage, claims processing and financial assistance **call 866-788- 9007 and select option #3.**



**RISK
IDENTIFIED**

MyUvealMelanoma.com

DecisionDx®-PRAME

DecisionDx-PRAME is an additional test that measures expression of a specific gene called PRAME. When a tumor has elevated PRAME (PRAME positive), the tumor may be more aggressive than a PRAME negative tumor. This report will indicate whether a tumor is PRAME positive or negative.

DecisionDx-PRAME is an optional test run at the same time as DecisionDx-UM. Your physician must request this test in conjunction with the DecisionDx-UM test.

DecisionDx®-UMSeq

DecisionDx-UMSeq is another optional panel that can determine whether there are somatic DNA mutations in seven important genes in your tumor. This information contributes to a comprehensive genomic picture of your tumor to help guide your care, and may also be useful in future research and development of treatments. No additional biopsy is necessary. It is important to remember that information from the gene sequencing panel is NOT a substitute for the DecisionDx-UM GEP test.



Laboratory Address:
3737 N. 7th Street, Ste. 160
Phoenix, AZ 85014

CLIA-certified,
CAP-accredited
laboratory

